Serial ultrasonographic imaging can predict failure after meniscus allograft transplantation

连续超声成像可以预测半月板同种异体移植术后的失败

阅读:2

Abstract

INTRODUCTION: Treatment monitoring after meniscus allograft transplantation (MAT) is challenging. Ultrasonographic (US) imaging has been proposed as a modality that may allow for treatment monitoring after MAT, but has yet to be clinically validated for this purpose. The objective of this study was to assess the capabilities for serial US imaging during the first year after surgery to predict short-term MAT failure. METHODS: Patients who had undergone Meniscus-only or Meniscus-Tibia MAT for treatment of medial or lateral meniscus deficiency were prospectively evaluated by US imaging at various time points after transplantation. Each meniscus was evaluated for abnormalities in echogenicity, shape, associated effusion, extrusion and extrusion with weightbearing (WB). RESULTS: Data from 31 patients with a mean follow-up of 32 ± 16 (range, 12-55) months were analysed. MAT failure occurred in 6 patients (19.4%) at a median time point of 20 (range, 14-28) months with 4 (12.9%) converted to total knee arthroplasty. US imaging was effective for assessing MAT extrusion and imaging with WB demonstrated dynamic changes in MAT extrusion. US characteristics that were significantly associated with higher likelihood for MAT failure included abnormal echogenicity, localised effusion, extrusion with WB at 6 months, and localised effusion and extrusion with WB at 1 year. CONCLUSIONS: US assessments of meniscus allografts at 6 months after transplantation can effectively determine risk for short-term failure. Abnormal meniscus echogenicity, persistent localised effusion and extrusion with weightbearing were associated with 8-15 times higher odds for failure, which occurred at a median of 20 months post-transplantation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。